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Vein bypass grafting is an integral component of cardiovascular surgical practice for both arterial and venous diseases. 
However, many of these grafts will eventually fail due fo either intrinsic or extrinsic causes. This review examines the 
current understanding and knowledge of venous histology, vein graft pathology and the associated endothelial nd smooth 
muscle cell physiology and pharmacology. In addition, the status of research on the therapeutic control of vein graft intimal 
hyperplasia and accelerated atherosclerosis is assessed. 
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Introduction 
Cardiovascular surgery as a surgical discipline is less 
than a century old. Its birth coincided with a change in 
the prevailing philosophy of surgical practice from 
removal to repair. The earliest experiments with 
venous autografts were those of Gluck, Exner and 
Hopfner. However, these vein grafts all failed. Carrel 
and Guthrie successfully pioneered experimental 
autogenous vein bypass grafting. 1 In 1906, Goyanes 
inserted the first autogenous vein graft into a human, 
using a popliteal vein as an interposition graft to 
bridge an arterial defect, following excision of a 
syphilitic popliteal aneurysm 2 and in the same year, 
Lexer interposed a segment of great saphenous vein to 
bridge an arterial defect following excision of a post- 
traumatic axillary artery aneurysm. 3 However, this 
patient died shortly thereafter and at autops~ a clamp 
induced, non-occluding thrombus on the inner wall of 
the axiUary artery was observed. This was the first 
description of the consequences of intimal injury. In 
the following two decades, vascular procedures did 
not gain popular acceptance because of inaccurate 
preoperative diagnoses and frequent perioperative 
distal thrombotic events. The development of contrast 
angiography and the introduction of heparin resolved 
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these major impediments to such an extent that the 
risk to benefit ratio for bypass procedures became 
acceptable. Kunlin in 1949 described the modern 
popliteal bypass 4 and Holden in 1950 reported the use 
of the saphenous vein to bypass an occluded super- 
ficial femoral artery. 5 By 1962, the development of 
selective coronary angiography allowed Sabiston to 
perform the first right coronary artery bypass proce- 
dure. 6 The art of coronary artery bypass grafting was 
further developed and refined by Garret and Fav- 
aloro. 7's Although refinements in techniques and 
suture materials continue to occur, the guiding princi- 
ples of the early surgeons are still applicable. Further 
advance in peripheral arterial vein bypassing came 
with the introduction of the in-situ technique. The 
impetus for the development ofthis technique was the 
belief that explantation of the vein produced consider- 
able endothelial and mural injury that was contribut- 
ing to the high failure rates. Although Rob performed 
the first modern successful in-situ bypass in 1959, 9 it 
was Hall who pioneered the principle, introduced 
technical modifications and developed a valvulo- 
tome. 1° The in-situ technique did not enter into 
widespread use until the reports of Leather and 
Karmody appeared, detailing impressive short- and 
long-term patency results. ~1"~2 The debate on the 
advantages of the in-situ technique compared to the 
reversed vein grafts is ongoing and at present it 
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Table 1. Mechanisms of vein graft failure 
Intrinsic Extrinsic 
Poor vein quality 
Missed valve/branch (in situ) 
Branch ligature placement 
Intimal flaps 
Intimal hyperplasia ( nastomotic or intra-graft) 
Accelerated atherosclerosis 
Ancurysmal degeneration 
Anastomotic problems 
Inflow tract stenosis or occlusion 
Outflow tract stenosis or occlusion 
Thromboembolism 
Graft sepsis 
Mechanical compression f the graft (entrapment or kinking) 
appears that there are equivalent patency rates for 
both types of grafts in all positions. 
Clinical graft patency of autogenous aphenous 
vein grafts in the arterial circulation can be divided 
into three temporal categories: early (0 to 30 days), 
short-term (30 days to 2 years) or long-term (greater 
than 2 years). Generically the causes of these failures 
may be classified as either intrinsic or extrinsic (Table 
1). Early failures are ascribed to either technical 
failures occurring at the anastomoses, the position of 
the graft, kinking of the graft or initial poor distal 
runoff and account for less than 5% of all vein graft 
occlusions. The number of occlusions due to technical 
difficulties or inappropriate graft placement into poor 
inflow/runoff tracts is unlikely to diminish further 
given the present level of vascular diagnosis and 
surgical expertise. Short-term failures are due pre- 
dominantly to the development of intimal hyperplasia 
within the graft. Generally, short-term patency rates 
range from 80-90% with a subsequent annual failure 
rate of 2 to 5%. Up to 30% of vein grafts will require 
intervention within two years due to the development 
of haemodynamically significant intimal hyperplastic 
13 lesions (graft stenoses). The etiology of long-term 
failure is still unclear but a combination of progression 
of the host's underlying disease, increased graft 
intimal hyperplasia nd the development of athero- 
sclerosis-like l sions within the vein graft appear to be 
the principal causes. 
The concept of the "failing graft", is one of a 
patent graft, whose patency is threatened by a 
haemodynamically significant lesion in the inflow/ 
outflow tracts or within the body of the graft. Salvage 
of "failing" and failed bypass grafts remains an 
important clinical and technical challenge. As many as 
80% of patients who present with recurrent limb 
ischaemia have an occluded graft and the patency of 
these occluded vein grafts after revision is often 
extremely poor. ~4' 25 This bleak outcome with occlu- 
sion has led to the evolution of graft surveillance 
programs to detect "failing" grafts and has spurred 
research on means to control the development of 
intimal hyperplasia. 
The increasing use of autogenous vein grafting 
procedures and the heightened awareness of its 
pathological sequelae has stimulated interest in 
venous biology and the biological consequences upon 
the vein of being placed in the arterial system. Studies 
of human veins harvested for bypass procedures have 
revealed that many have abnormal histologic and 
physiologic attributes. 16-~'° Furthermore, the quality of 
the saphenous vein can have significant clinical 
consequencesY' 22 Vein grafts in the arterial circula- 
tion, must be considered as a viable, constantly 
adapting and evolving conduit. This review examines 
the physiology, pharmacology and pathology of veins 
and vein grafts in the preoperative, perioperative and 
postoperative periods. Better definition and under- 
standing of the biological events during these periods 
should allow an accurate definition of the pathophy- 
siology of vein graft failure and the development of 
new interventional therapies. 
Preoperative Period 
The wall of a vein is traditionally divided into three 
anatomic layers: the intima, the media and the 
adventitia. The intima is composed of a thin layer of 
endothelial cells beneath which is a fenestrated base- 
ment membrane, a subendothelial matrix of glycopro- 
teins and connective tissue elements, and occasional 
intimal cells. In the media, the smooth muscle cells are 
arranged in an inner longitudinal and an outer 
circumferential pattern with collagen and elastic fibrils 
interlaced. The elastic fibrils appear to be orientated 
predominantly in a longitudinal direction. The adven- 
titia forms the outer layer of vein wall and is often 
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thicker than the media and consists of a loose network 
of longitudinally orientated collagen bundles and 
scattered fibroblasts through which the vasa vasorum 
of the vein pass. The vasa vasorum of veins form an 
anastomotic plexus that provides resistance to ischae- 
mic injury when there is local interruption of these 
vessels. 23'24 On occasion, longitudinal or spirally 
arranged smooth muscle cells may appear in areas of 
the adventitia djacent o the media. The endothelial 
cells appear as flat polygonal cells with large centrally 
placed nuclei surrounded by a thin cytoplasm with 
the usual organelles and large numbers of plasma- 
lemmal vesicles. 2s The junctions between the cells are 
mainly of a long occluding type and are considered 
more permeable than those of the arterial circula- 
tion. 24"25 Numerous microvilli can be demonstrated 
on the luminal surface and lesser numbers of cyto- 
plasmic processes penetrate the subendothelial 
matrix. 25'26 The smooth muscle cells contain con- 
tractile fibres with dense bodies, prominent subsur- 
face vesicles and the usual organelles. Veins are highly 
compliant over the range of venous pressures and are 
relatively non-compliant at arterial pressures. 27Veins 
have a high degree of lactic dehydrogenase activity s 
with lesser amounts of the other oxidative nzymes. 
In addition, veins appear to have a different metabolic 
profile and tissue content compared to arteries which 
may in part account for the distinct patterns of lipid 
29- 33 accumulation found between veins and arteries. - 
Although there is no difference in total protein 
content, the amount of collagen appears to be greater 
in the saphenous veins. 33 The total content of glycosa- 
minoglycans is also similar in the saphenous veins 
and internal mammary arteries, although the major 
component present in the internal mammary artery is 
heparan sulfate while in the saphenous vein, derma- 
tan sulfate is the dominant glycosaminoglycan. 33 In 
association with these structural and biochemical 
differences, there are differences in the vasomotor 
function of the saphenous veins compared to the 
internal mammary arteries. Nitric oxide and prostacy- 
din mediated relaxation responses of saphenous veins 
are much less and the maximal contractile forces 
generated are much greater than the internal mam- 
mary artery. 34 In addition, local angiotensin convert- 
ing enzyme activity which converts angiotensin I to 
angiotensin II and degrades bradykinin (a potent 
mediator of nitric oxide release) is greater in the 
saphenous vein compared to the internal mammary 
artery. 34 Saphenous veins demonstrate a spectrum of 
pre-existing pathological conditions ranging from 
significantly thickened walls to post phlebitic changes 
and varicosities at the time of harvest. Between 2 and 
5% of these veins are unusable and up to 12% can be 
considered "diseased". 21These "diseased" veins have 
a patency rate one half that of "non-diseased" con- 
trols. The etiology of the venous diseases observed are 
multifactorial in origin and at the present time without 
gross morphological evidence of disease there is no 
clear prognostic indicator to discriminate those veins 
which should be rejected as grafts. 21'22 It is apparent 
that most saphenous veins excised have a degree of 
intimal thickening and show altered in vitro smooth 
muscle cell contractility which are not dependent on 
donor age but can be positively correlated with donor 
gender. 17'2°'35-37 Endothelial mediated relaxation 
appears to be intact in the saphenous veins of patients 
undergoing peripheral vascular surgery, although 
there are suggestions that saphenous veins have a 
decreased ability to release intraluminal nitric oxide 
and that smoking can impair both nitric oxide and 
prostacyclin mediated responses. 19'34'38 A recent 
study of the morphological features of veins which 
have been used for bypass has shown intimal thicken- 
ing and histological evidence of early atheromatous 
changes in the intima; 39 additionally, the compliance 
of the vein wall can be correlated with the intimal 
thickness of the vessel. 4° Primary cultures from 
saphenous veins of patients undergoing venous 
bypass reconstruction suggest that the smooth muscle 
cell phenotypes present demonstrate a spectrum of 
sensitivity to growth inhibition by heparin. 41 
Perioperative Period 
Perioperative manipulations of veins prior to their 
insertion have been shown to produce significant 
tissue damage. Such implantation injury leads to 
endothelial dysfunction, endothelial cell injury, endo- 
thelial denudation and smooth muscle cell injury each 
of which are important factors in the initiation of 
intimal hyperplasia. It is now recognised that every 
effort should be made to reduce thedegree  of 
implantation injury that a vein graft suffers. 42~45 The 
basic principles of optimal saphenous vein procure- 
ment have been established by many studies and 
include as strict as possible adherence to the "no 
touch" technique, where there should be minimum 
manual and instrumental contact with the vessel, 46 the 
use of papaverine as a smooth muscle cell relax- 
ant, 47-5° the use of an appropriate physiological 
storage solution, the avoidance of cold procurement 
48 51 54 solutions ' - and the control of distension pres- 
sures to -100mmHg during vein perfusion. 53'55-57 
Storage of vein grafts in non-physiological solutions 
(i.e. solutions which do not have an electrolyte 
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composition, pH, osmolarity and temperature close to 
serum) leads to morphological damage, loss of endo- 
thelium dependent vasomotor function (decreased 
prostacyclin and NO release) but apj~ears to leave 
smooth muscle cell contractility intact, s°' 59 During this 
period of storage the vein grafts do not experience 
significant hypoxia. 6° Furthermore, injudicious disten- 
sion of veins ( > 100mmHg) can produce both morpho- 
logical and functional injuries to the endothelial and 
smooth muscle cells of the vein graft. 53' 56, 57, 61-65 The 
use of physiological solutions containing papaverine 
with osmotic and pH characteristics loser to serum or 
the use of whole blood to store vein grafts has 
improved the quality of the harvested vein graft, as 
assessed by functional biochemical and histological 
studies. There appears to be a direct relationship 
between the morphological integrity of the vein graft 
prior to grafting and its later histopathological appear- 
43 45 ance and function. ' Poorly prepared vein grafts 
develop significantly greater intimal hyperplasia nd 
increased smooth muscle cell contractility comPared 
to carefully prepared vein grafts. 43' 45 
The in-situ technique is considered to prevent 
many of the problems associated with implantation 
injury particularly with regard to the body of the vein 
graft. In-situ vein bypass grafts appear to have a 
greater degree of endothelial' preservation and supe- 
rior endothelial cell function compared to reversed 
vein gTafts. 66-73 Two recent articles have suggested 
that the use of a valvutome in the in-situ vein results in 
near total endothelial cell loss with an associated 
endothelial and smooth muscle cell functional deficit 
implying that thisparticular type of in-situ technique 
74, 75 is not beneficial. ' It is to be expected that the 
passage of a valvutome along the length of the vein 
which is akin to the passage of an embolectomy 
catheter along an artery would result in significant 
vessel wall injuries. However, not all in-situ tech- 
niques require the full length passage of a valvutome 
and studies using different echniques would suggest 
that there is a significant morphologic and functional 
benefit to the technique in the perioperative 
period. 66-73 
strated that following exposure to the arterial environ- 
ment, the cells experience severe stretching and 
increased tangential stress both of which contribute to 
endothelial cell damage. 24'76 Within 24 hours, the 
endothelial cells are sandwiched between adherent 
luminal and infiltrating subendothelial polymorpho- 
nucleocytes with platelet deposition on the endothe- 
lial surface. In addition, there is extensive sub- 
endothelial oedema which reflects a combination of 
increased transmural f ux and stretch damage due to 
the vein graft's distension by arterial blood pressure. 
In experimental vein grafts smooth muscle cell pro- 
liferation occurs within the first 72 hours and con- 
tinues for at least 7 days after insertion. 77' 78 Asso- 
ciated with the onset of proliferation, there are 
changes in specific membrane G-protein subunit 
expression i  the smooth muscle cells with the de novo 
expression of o~ i and m s subunits. Microscopic devel- 
opment of intimal hyperplasia occurs later, from day 3 
to 5 and increases rapidly between 7 to 14 days. There 
is a loss of contractile function with the onset of 
smooth muscle cell proliferation in the vein grafts. 
This contractile function returns with time after day 7. 
The pattern of smooth muscle cell contractility is 
markedly different to the control vein and is asso- 
ciated with additional changes in the functional 
coupling of receptors to G-proteins in vein grafts. 79 
Histological surveys of human saptienous vein 
grafts have been derived from specimens obtained at 
autopsy or at re-operation, z4" 80 Vein grafts obtained in 
the early postoperative period (< 24 hrs) show focal 
loss of endothelial cells particularly at the perianasto- 
motic areas and fibrin deposition on the intima. An 
increased permeability of the endothelium has been 
observed with polymorphonucleocytes and platelet 
adherence to denuded areas within one day post- 
operatively. In the following four days, the deposition 
of intimal fibrin and the accumulation of various 
blood cell elements on the endothelial surface become 
more prominent. In addition, focal areas of denuded 
endothelium due to cells sloughing are also observed. 
By days 7 to 14, the endothelial cell layer in these 
grafts can be redefined and at this time intimal smooth 
muscle cells can be identified. 24 
Postoperative Period 
The preservation of the endothelial cell layer during 
harvest has changed the sequence of histological 
changes observed after implantation. It is now appar- 
ent from experimental nd angioscopic studies that 
the endothelium is preserved after implantation into 
the arterial circulation. Current studies have demon- 
Mechanisms of Vein Graft Failure 
Intimal hyperplasia is the universal response of a vein 
graft to insertion into the arterial circulation and is 
considered to result from both the migration of 
smooth muscle cells out of the media into the intima 
and proliferation of these smooth muscle cells; later 
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the smooth muscle cells deposit an extracellular 
matrix. Macroscopically, intimal hyperplastic lesions 
appear pale, smooth, firm and homogenous; they are 
uniformly located between the endothelium and the 
medial smooth muscle cell layer of a vein graft. 8~" s2 
Due to the lack of a well defined internal elastic 
lamina in veins, the separation between intimal and 
medial layers may be delineated by identification of 
the demarcation between the criss-cross orientation of 
the intimal hyperplastic smooth muscle cells and 
circular smooth muscle cells of the media; the outer 
limit of the media was defined by the interface 
between the circular smooth muscle cells of the media 
and the connective tissue of the adventitia. In general, 
intimal hyperplasia is a self-limiting process which 
does not produce luminal compromise and usually 
becomes quiescent within 2 years of graft insertion. 
However, in focal areas, the intimal hyperplastic 
8144 process can proceed to significant stenosis. The 
first report of a vein graft stenosis was in 196585 but it 
was not until 1971 that the first report appeared citing 
intimal hyperplasia s the cause of the late occlusion 
in an aorto-coronary vein bypass graft 86 but recent 
studies of peripheral vein grafts have documented 
that the majority of stenotic lesions which develop in 
a graft are composed of intimal hyperplastic 
tissue.S3, 84 
The precise initiating stimuli for intimal hyper- 
plasia have not been fully defined but it appears to be 
the response of the vascular smooth muscle cells to a 
combination of physical cellular and humoral factors 
accompanied by dysfunctional endothelial regula- 
tion. 8~'82'a7's8 Fibroblast growth factors contribute 
significantly to the medial proliferation of smooth 
muscle cells while the presence of either endogenous 
or exogenous platelet derived growth factors promote 
the migration of smooth muscle cells from the media 
to the intima. Several other mediators of both the 
tyrosine kinase (IGF-1, TGF-~, ~-thrombin and inter- 
leukin-l~) and G-protein (angiotension II, endothelin- 
1, serotonin) coupled membrane receptors have been 
shown to participate in these initial events. The 
mediators of the intimal proliferative response which 
occurs after migration from the media are unclear as 
are the factors which induce smooth muscle cell 
proliferation to wane and the synthesis of extracellular 
matrix to begin; however, there are suggestions that 
the activity of transforming growth factor-~ isoforms 
and endothelial cells are important in this transition 
from an "activated" state to a relative "quiescent" 
state.81, 82, 87 
The majority of vein graft stenoses from human 
peripheral bypass grafts can be classified as intimal 
hyperplasia being highly cellular consisting predom- 
inantly of smooth muscle cells with a variable amount 
of connective tissue features imilar to the intimal 
hyperplasia of animal models. During the initial 
perioperative period after saphenous vein coronary 
grafting, early stenosis and occlusions occurs in 5-8% 
of grafts due to intimal hyperplasia. 13" 22, 83, 84, 89 Pri- 
mary cultures from these stenotic lesions have sug- 
gested that the smooth muscle cell phenotype present 
is more resistant o the action of growth inhibitors 
such as heparin than other areas of the graft. 9° 
Saphenous vein grafts excised from patients under- 
going revision surgery continue to exhibit dose- 
dependent contractile responses to the physiologically 
relevant agonists which are markedly reduced com- 
pared to fresh saphenous veins.91-gBGrafting of saphe- 
nous veins appears to result in the loss of endothe- 
lium-dependent relaxation responses to the 
receptor-coupled agonists, but not to the receptor- 
independent agonists. 34' 92-95 It is also suggested that 
endothelium mediated relaxation is preserved in 
retrieved human coronary vein bypass grafts but that 
there are significant decreases in this response with 
increasing severity of the intimal esions. 96 In addition 
to the decreased NO mediated responses, there is a 
decrease in prostacyclin mediated responses in 
retrieved vein grafts. 34 Associated with the decrease 
both NO and prostacyclin activity, the local intrinsic 
fibrinolytic activity of vein grafts is reduced compared 
to ungrafted veins. 97' 98 This combination of decreased 
anti-aggregatory potential and fibrinolytic activity 
results in an increased thrombogenic surface and it is 
notable that two-thirds of vein grafts removed uring 
redo coronary artery bypass operation show evidence 
of mural or occlusive thrombus. 99
Changes in haemodynamic parameters have been 
shown to affect the structure of both normal and 
diseased vessels, °° Haemodynamic alterations are 
implicated in the intimal response of vein 
grafts.40,101-122 Recent evidence suggests that defor- 
mation of smooth muscle cells by arterial haemody- 
namics can lead to activation of protein tyrosine 
kinases and thereby initiate smooth muscle cell pro- 
liferation. 113 Vein grafts with lower flows are asso- 
ciated with greater intimal thickening. ~°5 Similarly 
low shear stress is also associated with increased 
development of intimal hyperplasia in vein 
206 208 grafts. ' Dobrin has shown in vein grafts that 
blood flow (closely associated with shear stress) is best 
associated with the formation of intimal hyperplasia 
and that deformation of the vessel wall in a circum- 
ferential direction is best associated with medial 
thickening, 1°9"m Similarly, Morinaga reported that 
accelerated intimal thickening develops in vein grafts 
under low flow conditions (poor distal runoff) and is 
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reversed when these vessels are re-implanted into a 
system with normal parameters of flow. 11° Several 
studies have shown that rigid external support of a 
vein graft reduces intimal hyperplasia nd can pre- 
serve endothelium dependent responses in vein 
grafts. 114-117 Other studies have suggested a role for 
increased wall tension in the development of intimal 
hyperplasia.107, 222 In a recent study, it has been shown 
that rabbit arterial vein grafts removed from the 
arterial circulation after 2 weeks and returned to the 
venous circulation for a further 2 weeks demonstrate a 
significant regression of both intimal and medial 
thickening in the re-implanted grafts with restoration 
of endothelium dependent relaxation to all agonists. 118 
A study by Fann using a similar procedure in a canine 
model has shown that vein graft intimal hyperplasia is
not reduced when a graft implanted for 12 weeks is 
returned to the venous circulation and harvested after 
an additional 12 weeks. 119 However, the medial area 
regresses ignificantly in this study suggesting that 
circumferential deformation of the vessel wall is the 
dominant factor in the stimulation of medial thicken- 
ing, while alterations in flow, are responsible for the 
decreases in intimal hyperplasia. 
Diffuse dilatation or expansion of vein grafts is 
often seen when they are used as aortorenal bypass 
grafts.16,120, 222 Approximately half of the vein grafts 
show a nonprogressive, uniform enlargement of the 
graft which is often as much as a 20% increase in the 
graft original transverse diameter. The factors respon- 
sible for this early dilatation may be a high flow rate 
and/or the expanding influence of the arterial pres- 
sure in tissue relatively unsupported by surrounding 
tissue. It has been suggested that the degree of dilation 
is most probably controlled by the concomitant devel- 
opment of intimal hyperplasia. Focal dilation or 
aneurysm formation has been reported in vein grafts 
irrespective of the site of insertion. 16" 122,-226 Although 
these aneurysms may be associated with athero- 
sclerotic changes, the tissue from many aneurysms 
often does not differ histologically from the non- 
aneurysmal portion of the patent vein grafts. 
With few exceptions patients who undergo vein 
bypass grafting have a significant degree of arteriop- 
ath3~ and concomitantly have one or more atherogenic 
risk factors present. Hypertension'in both human and 
experimental models does not affect he development 
of intimal hyperplasia in the short or long term. 127-13° 
Furthermore, it appears that hypertension is not 
associated with the later development of vein graft 
atherosclerosis. 127 In contrast, both experimental nd 
clinical studies have shown an association of hyper- 
lipidemia with the development of intimal hyper- 
plasia/atherosclerosis and with higher vein graft 
failure rates. 127'131"132 Clinically, diabetes does not 
appear to impact significantly on vein graft patency 
but experimentally, it does increase short term intimal 
hyperplasia development. 127' 1BB In cases of combined 
hypertension and hyperlipidemia, there appears to be 
no additive effects on intimal hyperplasia develop- 
ment in vein grafts compared to hyperlipidemia alone. 
In contrast, however, the combined presence of dia- 
betes and hyperlipidemia has a significant additive 
effect on the formation of intimal hyperplasia in 
experimental vein grafts. Interestingl3¢ the profile of 
vasomotor function of vein grafts, in situations where 
more than one atherogenic risk factor is present, is 
attenuated compared to the comparative situation 
where only one disease state is present and the 
observed profiles are very similar to those observed in 
retrieved human vein grafts. 79 
The intimal hyperplastic lesions of vein grafts 
retrieved one month after aorto-coronary bypass in 
humans have been shown to consist of proliferating 
smooth muscle cells with only scattered macrophages 
in the subendothelium. TM Under hyperlipidemic con- 
ditions, venous tissue has demonstrated anavidity for 
the uptake of serum lipid surpassing that of arterial 
29 135 tissue in the same species. ' Intimal hyperplastic 
lesions of experimental hypercholesterolemic vein 
grafts are composed predominantly of lipid-laden 
smooth muscle cells with macrophages in various 
stages of foam cell formation interspersed between 
these cells. 131'132'136 Macrophages are one of the 
principal cells involved in the development of athero- 
sclerosis through the oxidation of lipoproteins and the 
137 139 formation of lipid peroxides. - Oxygen free radi- 
cals and lipid peroxides also interfere with the 
vasomotor function of both endothelial and smooth 
muscle cells. 14°-143 Reduction of both cholesterol and 
low density lipoproteins (LDL) is considered useful in 
slowing and preventing atherogenesis. 144 In experi- 
mental vein grafts, reduction in serum cholesterol by 
20% in hypercholesterolemic rabbits with either lovos- 
tatin therapy or ileal bypass surgery has resulted in a 
significant decrease in total graft cholesterol con- 
tent. 145 In rabbits, a 74% reduction in serum choles- 
terol concentrations over the first 28 postoperative 
days is associated with a 26% reduction in graft 
intimal thickness and the macroscopic absence of 
atheromatous lesions in the graft wall compared to 
untreated controls. 146 A reduction of 26% in serum 
cholesterol in patients at 4 years after aorto-coronary 
bypass surgery using a combined cholestipol and 
niacin therapy for two years reduced the occurrence of 
stenotic and occlusive lesions in the vein bypass grafts 
of 16% of the patients suggesting that reduction of 
serum cholesterol may improve long term vein graft 
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patency. 147 With particular egard to peripheral vein 
graft stenoses, no association has been found with 
patient age, sex, presenting symptoms, hypertension, 
diabetes or the condition of the outflow vessel. The 
incidence of stenosis appears higher the longer (i.e. the 
more distal) the insertion. 14s Other studies have 
suggested that platelet dysfunction, hyperfibrinogene- 
mia and lipoprotein (a) may be associated with an 
increased risk of stenosis development. 149' 1so At pre- 
sent the association with smoking and vein graft 
stenosis is equivocal. 148' 150 
Vein grafts retrieved from patients with angio- 
graphic evidence of occlusive disease demonstrate 
histologic features of atherosclerosis. 128" 129,151-154 The 
earliest these lesions have been seen is six months 
after implantation. Thus, it appears that these late 
occlusions of vein bypass grafts are due to the 
development of a rapidly progressive and structurally 
distinct form of atherosclerosis which has been termed 
"accelerated atherosclerosis" in order to distinguish it 
from "spontaneous atherosclerosis'. 82 Accelerated 
atherosclerosis is morphologically different o sponta- 
neous atherosclerosis in that its lesions appear to be 
diffuse, more concentric and have a greater cellularity 
with varying degrees of lipid accumulation and 
Table 2. Therapeutic control in experimental models 
mononuclear cell infiltration. The syndrome of accel- 
erated atherosclerosis shares many of the pathophy- 
siological features of intimal hyperplasia, however, the 
prime mediators of this type of atherosclerosis are 
likely to be the macrophage. In addition the endothe- 
l ium overlying accelerated atherosclerotic lesions 
expresses the class II antigens which are not observed 
in spontaneous atherosclerosis. 
Therapeutic Control of Intimal Hyperplasia 
Intimal hyperplasia remains one of the major obstacles 
to long term graft patency. 155 Minimising the degree of 
implantation injury appears to be a simple and 
effective first step. Therapies to limit its development 
in vein grafts continues to attract considerable atten- 
tion; however, no effective clinical regimen is pres- 
ently available to counter the intimal hyperplastic 
response found in vein grafts. The use of aspirin is 
associated with a decrease in early thrombotic events 
in vein grafts but has not been documented to reduce 
the incidence of restenosis or the development of 
atherosderosis. 156 The various class of compounds 
which have shown promise in experimental vein 
Class Compound Outcome 
Solutions Warm iso-osmotic physiological solutions Yes43, 45 
Mechanical PTFE support Yes116,117 
Anti platelet Aspirin /dipyridamole Yes 157' 158/No159 
Antioxidant Desferrioxamine manganese Yes 16° 
21-aminosteroids Yes 161 
Ca 2 ÷ channel Blocker Verapamil Yes 162 
Steroids Prednisolone Yes 163 / No 164 
Immunosuppression Cyclosporine Yes lss 
ACE inhibitors Captopril Yes 165 
Cilazapril No ~ss 
Receptor Antagonists Ketanserin Yes 166 
Prazosin NO 167 
Heparins Heparin Yes16S, 169 / No~70 
LMW heparin NO 171 
Peptides Angiopeptin Yes ~7z 
Amino acids L-arginine Yes 173 
f~-3 Polyunsaturated Fatty Ac ids  Eicosapentaenoic acid Yes174,175 
Yes: intimal hyperplasia reduced by more than 25% of control 
No: No reduction i  intimal hyperplasia or a reduction of less than 25% of control 
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bypass models are shown in Table 2. However, few 
have successfully been transferred to the clinical 
arena. Furthermore, one must be cautious in inter- 
preting the results of clinical trials which have 
attempted to pharmacologically reduce the develop- 
ment of angioplasty induced hyperplastic restenosis, 
because in many respects, vein graft intimal hyper- 
plasia is a distinct entity. 
Conclusion 
The saphenous vein remains a mainstay of surgical 
therapy for arterial occlusive disease. As a biologic 
conduit, it has distinctive native properties and a 
degree of intrinsic degeneration which can impact on 
subsequent performance. The greater understanding 
of the sequence of events in the preoperative, perio- 
perative and postoperative phases of vein grafting 
which have been gleaned from experimental and 
clinical studies has allowed a clearer definition of vein 
graft pathophysiology. Vein grafts are living, con- 
stantly evolving conduits that adapt to the arterial 
circulation with the development of intimal hyper- 
plasia but subsequently develop accelerated athero- 
sclerosis each of which compromises patency. At 
present, intimal hyperplasia is the principal impedi- 
ment to more durable grafts. The growing under- 
standing of the pathobiology of vein grafts will 
ultimately produce practical therapeutic strategies to 
enhance graft function and control intimal 
hyperplasia. 
Acknowledgements 
The authors would like to express their gratitude to Dr K.G.M. 
Brockbank and Ms L. Barber for their assistance and advice in the 
preparation Of this manuscript. 
Grant Support: U.S. Public Health Service HL 15448. American 
Heart Association (NC Affiliate) NC 92-GB-31 
Mark G. Davies is supported by a N.I.H. Fogarty International 
Research Fellowship (TW 04810) and holds a Royal College of 
Surgeons in Ireland Surgical Travelling Fellowship and a Trinity 
College Dublin Postgraduate Scholarship. 
References 
1 CAI~REL A, GUTHr~E CC. Anastomosis of blood vessels by the 
patching method and transplantation of the kidney. JAMA 
1906; 47: 1648-1651. 
2 GOYANES DJ. Substitution Plastica de las Arterias por Pas Vena 
o Arterioplastica Venosa, Aplicado Como Naevo Metodica 
Tratamiento de los Anemismas. El Siglo Medico 1906 Sept; 1: 
346-362. 
3 LEXER F. Die ideale Operation des Arteriellen und des Arter- 
iennen-venosen aneurysma. Archly Kiln Chir 1907; 83: 
459-460. 
4 KtZNL~ J. Le traitment de l'arterite obliterante par la greffe 
veineuse. Arch Mal Coeur 1949; 42: 371-372. 
5 HOLDEN WD. Reconstruction of the femoral artery for athero- 
sclerotic thrombosis. Surgery 1950; 27: 417. 
6 SABISTON DC Jr. The Coronary Circulation: The William F. 
Reinhoff, Jr. Lecture. John Hopkins Med J 1974; 134: 314-320. 
7 GARRETT HE, DENNIS EW, DEBAKEY ME. Aortocoronary bypass 
with saphenous vein graft: Seven year follow up. lAMA 1973; 
223: 792-794. 
8 FAVALORO RG. Saphenous vein autograft replacement of severe 
sequential coronary artery occlusion. Operative technique. Ann 
Thorac Surg 1968; 5: 334-339. 
9 ROB CG. Discussion following Szilagyi DE, Smith R_F, Elliott JP. 
Venous autografts in femoropopliteal rterioplasty. Observa- 
tions in treatment of occlusive disease. Arch Surg 1964; 89: 
113-125. 
10 HALL K. The great saphenous vein used in situ as an arterial 
shunt after extirpation of the vein valves. A preliminary report. 
Surgery 1962; 51: 492-495. 
11 LEATHER RP, POWERS SB, KARMODY AM. A reappraisal of the in 
situ saphenous vein arterial bypass: its use in limb salvage. 
Surgery 1979; 86: 453461. 
12 LEATHER RR, SHAH DM, BUCHBINDER D, ANNEST SJ, KARMODY 
AM. Further experience with the saphenous vein used in situ 
for arterial bypass. Am J Surg 198l; 1981: 142-144. 
13 MILLS JL, FUJITANI RIV[, TAYLOR SM. The characteristics and 
anatomic distribution of lesions that cause reversed vein graft 
failure: a five year prospective study. J Vasc Surg 1993; 17: 
195-204. 
14 WI4ITTEMO~E AD, CLOWES AW, COUCH NP, MANNICK JA. 
Secondary femoropopliteal reconstruction. Ann Surg 1980; 193: 
35-42. 
15 GREEN RM, OURIEL K, RICOTTA JJ¢ DEWEESE JA. Revision of fared 
infrainguinal bypass graft: principles of management. Surgery 
1986; 100: 646-653. 
16 STANLEY JC, ERNST CB, FRY WJ. Fate of 100 aortorenal vein 
grafts: characteristics of late graft expansion. Aneurysmal 
dilatation and stenosis. Surgery 1973; 74: 931-944. 
17 THIENE G, MIAZZI P, VALSECCHI M, et al. Histological survey of 
the saphenous vein before its use as autologous aortocoronary 
bypass graft. Thorax 1980; 35: 519-522. 
18 MmRoy CM, SCOTT DJA, BEARD JD, HORROCKS M, BRADFIELD 
JWB. Histological appearance of the long saphenous vein. J 
Pathol 1989; 159: 311-316. 
19 SCHWARTZ LB, RADIC ZS, O'DONOHOE MK, MCCANN RL, HAGEN 
P-O. Saphenous vein endothelium dependent relaxation in 
patients with peripheral vascular disease. Ann Vasc Surg 1992; 
6: 425-432. 
20 DAVIES MG, BROCKBANK KGM, HAGEN P-O. The relationship of 
human saphenous vein intimal area to age and gender. Vasc 
Surg 1992; 26: 700-704. 
21 PANETTA TF, MAR!N IVIL, VEITH FJ/ et al. Unsuspected pre- 
existing saphenous vein disease: an unrecognized cause of vein 
bypass failure. J Vasc Surg 1992; 15: 102-112. 
22 VARTY K, ALLEN KE, BELL PRF, LONDON NJM. Infrainguinal vein 
graft stenosis. Br ] Surg 1993; 80; 825-833. 
23 CHEANVESHI C, EFF1ER DB, HOOPER JR. The structural study of 
the saphenous vein. Ann Thorac Surg 1976; 20: 636-645. 
24 Cox JL, CHAISSON DA, GO~ILIEB AI. Stranger in a strange land: 
the pathogenesis of saphenous vein graft stenosis with empha- 
sis on structural and functional differences between veins and 
arteries. Prog Cardiovasc Dis 1991; 34: 45q58. 
25 SrMION~SCU M, SIMIONESCU M. Endothelial Cell Biology in Health 
and Disease. (1st ed.) New York: Plenum Press, 1988. 
26 MERRILEES MJ, SHEpFt-IERD AJ, ROBINSON MC. Structural features 
of saphenous vein and internal thoracic artery endothelium: 
correlates with susceptibility and resistance to graft athero- 
sclerosis. J Cardiovasc Surg 1988; 29: 639-646. 
Eur J Vasc Endovasc Surg Vol 9, January 1995 
Vein Graft Pathophysiology 15 
27 WESLY RLR, VAISHNAU RN, FUCHS JCA, et al. Static linear and 
nonlinear elastic properties of normal and arterialized venous 
tissue. Circ Res 1975; 37: 509-520. 
28 McCABE M, CUNNINGHAM J, WYATT AP, ROTHNIE NG, TAYLOR 
GW. A histological and histochemical examination of auto- 
genous vein grafts. Br J Surg 1967; 54: 147-155. 
29 FucHs JCA, HAGEN P-O, OLDHAM HNJ, SABISTON DE. Lipid 
composition i  venous arterial bypass grafts. Surg Forum 1972; 
23: 139-141. 
30 LARSON RIN{, HAGEN P-O, FUCHS JCA. Lipid biosynthesis in 
arteries, veins and venous grafts (abstract). Circulation 1974; 30 
(Suppl III): 139. 
31 HASEGAWA M. Rheological properties and wall structure of 
large veins. Biorheology 1983; 20: 531-545. 
32 SHAFI S, PAL~SKI W, BORN GVR. Comparison of uptake and 
degradation of low density lipoproteins by arteres and veins of 
rabbits. Atherosclerosis 1987; 66: 131-138. 
33 SIisTo T, YLA-HERTTUALLA S, LUOMA J, IhCKKINEN H, NIKKARI T. 
Biochemical composition of human internal mammary artery 
and saphenous vein. J Vasc Surg 1990; 11: 418422. 
34 LOSCHER TF. Vascular biology of coronary bypass grafts. 
Coronary Artery Disease 1992; 3: 157-165. 
35 BouIssou I-{/ JULIAN M, PIERRAGGI MT, et al. Vein morphology. 
Phlebology 1988; 3: 1-11. 
36 LOWELL RC, GLOVICZKI P, MILLER VM. In vitro evaluation of 
endothelial and smooth muscle function of primary varicose 
veins. J Vasc Surg 1992; 16: 679-686. 
37 BROCKBANK KGM, DAVIES MS, FIELDS SM, PALLOS LL, HAGEN 
P-O. The relationship of human saphenous vein smooth muscle 
cell contractile responses to donor age. Vasc Surg 1994; 28: in 
press. 
38 HIGMAN DJ, GREENHALGH RM, POWELL JT. Smoking impairs 
endothelium dependent relaxation of saphenous vein. Br J Surg 
1993; 80: 1242-1245. 
39 DAVIES AH, MAGEE TR, BAIRD RN, SHEFFIELD E, HORROCKS M. 
Pre-bypass morphological changes in vein grafts. Eur ]Vasc 
Surg 1993; 7: 642-647. 
40 DAVIES AH, MAGEE TR, BAIRD RN, SHEFFIELD E, HORROCKS M. 
Vein compliance: a preoperative indicator of vein morphology 
and of veins at risk of vascular graft stenosis. Br ] Surg 1992; 79: 
1019-1021. 
41 MUNRO EN, CHAN P, PATEL M, et al. Intimal hyperplasia: the 
variable response of the human smooth muscle cell (abstract). 
XXI World Congress of the International Society for Cardiovasculara 
Surgery. Lisbon Portugal: 1993: 107. 
42 ADCOCK GD. Vein grafts: implantation i jury. ] Vasc Surg 1989; 
10: 587-589. 
43 QuisT WC, LoGERFO FW. Prevention of smooth muscle cell 
phenotypic modulation in vein grafts: a histomorphometric 
study. J Vasc Surg 1992; 16: 225-231. 
44 CAVALIARI N, ABEBE W, HUNTER WJ, et al. University of 
Wisconsin solution prevents intimal proliferation in canine 
autogenous vein grafts (abstract). VIIth Annual Meeting of the 
European Society for Vascular Surgery. Barcelona, Spain: 1993: 
44. 
45 DAVIES MG, HAGEN P-O. Influence of perioperative storage 
solutions on long term vein graft function and morphology. 
Ann Vasc Surg 1994; 8: 150-157. 
46 GOTTLOB R. The preservation of the venous endothelium by a 
dissection without ouching and by an atraumatic technique of 
vascular anastomosis. Min Chir 1977; 32: 693--700. 
47 HAUDENSCHILD CC, GOULD KE, QUIST WC, LoGERFO FW. 
Protection of endothelium in vessel segments excised for 
grafting Circulation 1981; 64: 101-107. 
48 LoGERFO FW, QUIST WC, CRANSHAW HM, HAUDENSCHILD CC. 
An improved technique for preservation of endothelial mor- 
phology in vein grafts. Surgery 1981; 90: 115-124. 
49 LoGE~o FW, QuIsT WC, CANTELMO NL, HAUDENSCHILD CC. 
Integrity of vein grafts as a function of initial intimal and media 
preservation. Circulation 1983; 68 (Suppl): 117-124. 
50 LoGERFO FW, HAUDENBCHILD CC, QUIST WC. A clinical tech- 
nique for prevention of spasm of endothelium in saphenous 
vein grafts. Arch Surg 1984; 119: 1212--1214. 
51 KARNSZ M, CHRISTMAN EW, DERRICK JR, et al. Use of cardioplegic 
solution for vein graft distension and preservation: a light and 
scanning electron microscopic study. Ann Thorac Surg 1981; 32: 
68-74. 
52 SOUTTIURAI V I STANLEY FC, FRY WJ. Ultrastructure of human 
and transplanted canine veins: effects of different preparation 
media. Surgery 1983; 93: 28-38. 
53 Bush HL, MCCABE ME, NABSETH DC. Functional injury of vein 
graft endothelium: role of hypothermia nd distension. Arch 
Surg 1984; 119: 770-774. 
54 SOLBERG S, LARSEN T, JORGENSEN L, et al. Cold induced 
endothelial cell detachment in human saphenous vein grafts. J
Cardiovasc Surg 1987; 28: 571-575. 
55 ADCOCK GLD, ADCOCK 0% WHEELER JR, GREGORY RT, SNYDER 
SOJ, GOYLF RC. Optimal techniques for harvesting and prepara- 
tion of reversed autogenous vein grafts for use as an arterial 
substitute. Surgery 1984; 96: 886-894. 
56 ANGELINI GD, PASSANI SR, BRECKENR1DGE IM, et al. Nature and 
pressure dependence of damage induced by distension of 
human saphenous vein coronary artery bypass grafts. Cardio- 
vasc Res 1987; 21: 902-907. 
57 DRIES D, MOHAMMAD SF, WOODWARD SC, NELSON RIM. The 
influence of harvesting technique on endothelial preservation 
in saphenous veins. J Surg Res 1992; 52: 219-225. 
58 ANGELINI GD, CHRISTI MI, BRYAN AJ, el al. Preparation of 
human saphenous vein for coronary artery bypass grafting 
impairs its capacity to release of endothelium-derived r laxing 
factor. Ann Thorac Surg 1989; 48: 417-421. 
59 SCHWARTZ LB, RADIC ZS, O'DONOHOE MK, MCCANN RL, 
MIKAT EM, HAGEN P-O. Functional and morphologi c endothe- 
lial damage in rabbit external jugular veins stored in heparinized 
normal saline. Blood Vessels 1991; 28: 511-519. 
60 DREGELID E, SVENDSEN E, SANDBERG S. Hypoxia does not occur 
during temporary storage of vein grafts in air equilibrated 
solutions. J Cardiovasc Surg 1992; 33: 143-149. 
61 MALONE JM, KlSCHER CW, MOORE WS. Changes in venous 
endothelial fibrinolytic activity and histology with in vitro 
distension and arterial implantation. Am J Surg 1981; 142: 
178-182. 
62 KENNEDY JH, LEVER MJ, ADDIS B J, et al. Changes in vein 
interstitium following distension for aortocoronary bypass. J 
Cardiovasc Surg 1989; 30: 992-995. 
63 ANGELINI GD, BRYAN AJ, WILLIAMS HMJ, et al. Distension 
promotes platelet and leukocyte adhesion and reduces short- 
term patency in pig arteriovenous bypass grafts, J Thorac 
Cardiovasc Surg 1990; 99: 433-439, 
64 SCHWARTZ LB, MASSEY MF, DAVIES MG, KLYACHKIN ML, 
HAGEN P-O, McCANN RL. Effect of in vitro pressurization on 
human saphenous vein vasoreactivity (abstract). FASEB J 1992; 
6: A1041. 
65 UNDERWOOD MJ, MORE R, WEERESENA N, FIRMIN RK, DEB- 
ONO DP. The effect of surgical preparation and in vitro 
distension on the intrinsic fibrinolytic activity of human saphe- 
nous veins. Eur J Vasc Surg 1993; 7: 518-522. 
66 Bush HL, JAKUBOWSKI JA, CURL R, DEYKIN D, NASBETH De. 
The natural history of endothelial structure and function in 
arterialized vein grafts. J Vasc Surg 1986; 3: 204-215. 
67 BOYD JM, STZVENS R, HARVEY A, SILVER D. Intimal integrity 
and fibrinolytic potential of reversed and in situ Vein grafts. J 
Vasc Surg 1987; 5: 614-621. 
68 CAMBmA RP, MEGERMAN J, ABBOTT WM. Endothelial preser- 
vation in reversed and in situ autogenous vein grafts. A 
quantitative experimental study. Ann Surg 1985; 202: 50-55. 
69 BUCHBINDER D, SINGH JK, KARMODY AM, LEATHER RP, SHAH 
DM. Comparison of patency rate and structural changes of in 
situ and reversed vein arterial bypass. J Surg Res 1981; 30: 
213-322. 
Eu r J Vasc Endovasc Surg Vol 9, January 1995 
16 M.G. Davies and P.-O. Hagen 
70 MAGNANT JG, WALSH DB, SCHNEIDER JR, JAMES TW, WAGNER 
R J, CRONENWETT JL. Differences in vasoreactivity of in situ and 
reversed vein grafts (abstract). J Vusc Surg 1992; 15: 1068. 
71 MILLER VM, BOWER TC, McCuLLOUGH JL, GLGVICZKI P, 
VANHOUTI'E PM. Endothelium-dependent responses in non- 
reversed (in situ) vein grafts. J Vasc Med Biol 1990; 2: 155-162. 
72 O'DONOHOE MK, MURCHAN PM, MARKS P, FEELEY J, FEELEY 
TM. Endothelium derived relaxing factor is absent in experi- 
mental in situ vein grafts. Eur J Vasc Surg 1993; 7: 144-150. 
73 DAVIES MG, KLYACHKIN ML, MASSEY MF, SVENDSEN E, 
HAGEN P-O. A comparative study of EDRF-mediated relaxation 
and smooth muscle cell function in arterial and venous vein 
bypass grafts. Cardiovasc Surg 1994; 2: in press. 
74 SAYERS RD, WATt PAC, MULLER S, BELL PRF, THURSTON H. 
Structural and functional muscle injury after surgical preparation 
of reversed and non-reversed (in situ) saphenous vein bypass 
grafts. Br J Surg 1991; 78: 1256-1258. 
75 SAYERS RD, WArt PAC, MULLER S, BELL PRF, THURSTON H. 
Endothelial cell injury secondary to surgical preparation of 
reversed and in situ saphenous vein bypass grafts. Eur J Vasc 
Surg 1992; 6: 354-361. 
76 DAVIES MG, KLYAEHKIN ML, DALEN H, MASSEY M, SVENDSEN 
E, HAGEN P-O. The integrity of experimental vein graft 
endothelium: implications on the etiology of early graft failure. 
Eur J Vasc Surg 1993; 7: 156-165. 
77 SCHWARTZ LB, PENCE JC, KERNS B J, IGLEHART JD, McCANN 
RL, HAGEN P-O. Kinetics of vein graft cell division and function. 
Surgical Forum 1991; 47: 362-365. 
78 ZWOLAK RM, ADAMS MC, CLOWES AW. Kinetics of vein graft 
hyperplasia: ssociation with tangential stress. J Vasc Surg 1987; 
5: 126-136. 
79 DAVIES MG, HAGEN P-O. Modelling the pathophysiology of
vein graft failure. J Vasc Surg 1994; 20: 139-141. 
80 SVENDSEN E, DALEN H, MOLAND J, ENGEDAL H. A quantitative 
study of endothelial cell injury in aortocoronary vein grafts. J 
Cardiovasc Surg 1986; 27: 65-67. 
81 CHERVU A, MOORE WS. An overview of intimal hyperplasia. 
Surg Gynecol Obstet 1990; 171: 433-447. 
82 IP JH, FUSTER V, BADIMON L, TAUBMAN MB, CHESEBRO JH. 
Syndromes of accelerated atherosclerosis: role of vascular injury 
and smooth muscle cell proliferation. JAm Coll Cardio11990; 15: 
1667-1687. 
83 SAYERS RD, JONES L, VARTY K, et al. The histopathology of
infrainguinal vein graft stenoses. Eur J Vasc Surg 1993; 7: 
16-20. 
84 BERKOWITZ HD, Fox AD, DEATON DH. Reversed vein graft 
stenosis: early diagnosis and management. J Vasc Surg 1992; 15: 
130-142. 
85 BRESLAU RC, DEWE~sE JA. Successful endophlebectomy of 
autogenous venous bypass grafts. Ann Surg 1965; 162: 251-254. 
86 GRONDIN CM, MEERE C, CASTONGUEY Y, et al. Progressive and 
late obstruction of an aortocoronary venous bypass graft. 
Circulation 1971; 43: 698-702. 
87 CLOWES AW, CLOWES MM, FINGERLE J, REIDY MA. Regulation 
of smooth muscle cell growth in injured artery. J Cardiovasc 
Pharmacol 1989; 14 (Suppl 6): S12-S15. 
88 CLOWES AW. Intimal hyperplasia nd graft failure. Cardiovasc 
Pathol 1993; 2 (Suppl): 179S-186S. 
89 KUNTZ RE, PIANA R, SCHN1TT S J, JOHNSON RG, SAFIAN RD, 
BAIM DS. Early ostial vein graft stenosis: management by 
athrectomy. Cath Cardiovasc Diag 1991; 24: 41-44. 
90 CHAN P, MUNRO E, PATEL M, et al. Cellular biology of human 
intimal hyperplastic stenosis. Eur J Vasc Surg 1993; 7: 129-135. 
91 HANET C, ROBERT A, WIJNS W. Vasomotor response to 
ergometrine and nitrates of saphenous vein grafts, internal 
mammary artery grafts and grafted coronary arteries late after 
bypass surgery. Circulation 1992; 86 (Suppl II): 210-216. 
92 PARK TC, HARKER CT, EDWARDS JM, MONETA GL, TAYLOR 
LM, PORTER JM. Human saphenous veins grafted into arterial 
circulation demonstrate altered smooth muscle and endothelial 
response, d Vasc Surg 1993; 18: 61-69. 
93 CROSS KS, DAVIES MG, ELSANADIKI MN, MURRAY JJ, MIKAT 
EM, HAGEN P-O. Long-term human vein graft contractility and 
morphology: A functional and histopathological study of 
retrieved coronary vein grafts. Br J Surg 1994; 81: 699-705. 
94 MILLER VM, REIGEL MM, HOLLIER LH, VANHOUTTE PM. 
Endothelium-dependent r sponses in autogenous femoral veins 
grafted into the arterial circulation of the dog. J Clin Invest 1987; 
80: 1350-1357. 
95 Lt~SEHER TF, DIEDERICtt D, SIEBENMANN R, et al. Differences 
between endothelium-dependent r laxation in arterial and in 
venous coronary bypass grafts. N Engl Y Med 1988; 319: 
462-467. 
96 Ku DD, CAUFIELD JB, KIRKLIN JK. Endothelium-dependent 
responses in longterm human coronary artery bypass grafts. 
Circulation 1991; 83: 402-411. 
97 YAO JST, BERGAN JJ, KWAAN HC. Quantification of fibrinolytic 
activity in venous and prosthetic arterial grafts. Arch Surg 1974; 
109: 163-167. 
98 RISEBERG B. Fibrinolysis in grafted arteries and veins. Hemostas 
1978; 40: 512-517. 
99 SOLYMOSS BC, NADEAU P, MILLETTE D, CAMPEAU L. Late 
thrombosis of saphenous vein coronary bypass graft related to 
risk factors (abstract). Circulation 1988; 78 (Suppl II): 140. 
100 GLAGOV S, ZARINS CK, MASAWA N, Xu CP, BASSIOUNY H, 
GIDDENS DP. Mechanical and functional role of non-athero- 
sclerotic intimal thickening. Frontiers of Medical and Biological 
Engineering 1993; 5: 37-43. 
101 BRODY WR, KOSEK JG, ANGELL Vg'V. Changes in vein grafts 
following aortocoronary bypass induced by pressure and ische- 
mia. J Thorac Cardiovasc Surg 1972; 64: 847-854. 
102 KENNEDY JH, WILTING DW, HWANG NHC, et al. Hydraulic and 
morphologic study of fibrous intimal hyperplasia in autogenous 
saphenous vein bypass grafts. J Thorac Cardiovasc Surg 1974; 67: 
805-813. 
103 FAULKNER SL, FISCHER RD, CONKLE DM, et al. Effect of blood 
flow rate on subendothelial proliferation in venous autografts 
used as arterial substitutes (abstract). Circulation 1975; 52 (Suppl 
1): 163, 
104 RITrGERS SE, KARAYANNACOS PE, GuY .IF, et al. Velocity 
distribution and intimal proliferation i  autologous vein grafts in 
dogs. Circ Res 1978; 42: 792-801. 
105 BERGUER R, HIGGINS RF, REDDY DJ. Intimal hyperplasia: an 
experimental study. Arch Surg 1980; 115: 332-338. 
106 KAMIYA A, TOGAWA T. Adaptive regulation of wall shear stress 
on intimal thickening of arterially transplanted autogenous veins 
in dogs. Am J Physiol 1980; 239: 14-21. 
107 KARAYANNACOS PE, RITTGERS SE, KAKOS GS, WILLIAMS TE, 
MECKSTROTH CV, VASKO JS. Potential role of velocity and wall 
tension in vein graft failure. J Cardiovasc Surg 1980; 21: 
171-178. 
108 MORINAGA K, OKADOME K, OHTSUKA K, et aL Effect of wall 
shear stress on intimal thickening of arterially transplanted 
autologous veins in dogs. J Vasc Surg 1985; 2: 430--433. 
109 DOBRIN PB, LITTOOY FN, GOLAN J, et al. Mechanical and 
histologic hanges in canine vein grafts. J Surg Res 1988; 14: 
259-260. 
110 MORINAGA K, EGUCHI H, MIYAZAKI T, OKADOME K, SUGI- 
MACHI K. Development and regression of intimal thickening of 
arterially transplanted autologous vein grafts in dogs. J Vasc Surg 
1987; 5: 19-30. 
111 DOBRIN PB, LITTOOY FN, ENDEAN ED. Mechanical factors 
predisposing to intimal hyperplasia nd medial thickening in 
autogenous vein grafts. Surgery 1989; 105: 393-400. 
112 SCHWARTZ LB, O'DoNoHOE MK, PURUT CM, MIKAT EM, 
HAGEN P-O, MCCANN RL. Myointimal thickening in experi- 
mental vein grafts is dependent on wall tension. J Vasc Surg 1992; 
15: 176-186. 
113 YANG Z, VoNSEGESSER L, STULZ P, TURINA M, LUSCHER TF. 
Pulsatile stretch and Platelet-derived Growth Factor (PDGF): 
important mechanisms for coronary venous graft disease 
(abstract), Circulation 1992; 86 (Suppl I): 1-84. 
Eur J Vasc Endovasc Surg Vol 9, January 1995 
Vein Graft Pathophysiology 17 
114 KARAYANNACOS PE, GEER J, GAST M, HODGES R, BOND G, 
VASKO, JS. Wall strain in arterial vein grafts (abstract). Clin Res 
1973; 21 813. 
115 BARRA JA, VOLANT A, LEROY JP, et al. Constrictive perivenous 
mesh prosthesis for preservation of vein integrity. J Thorac 
Cardiovasc Surg 1986; 92: 330-336. 
116 KOHLER TR, KIRKMAN TR, CLOWES AW. The effect of rigid 
external support on vein graft adaptation to the arterial 
circulation. J Vasc Surg 1989; 9: 277-285. 
117 HoPsoN SB, LusT RM, ZERI RS, et al. The effects of wall tension 
on the development of intimal development of intimal hyper- 
plasia in vein grafts. XXIst World Congress of the International 
Society for Cardiovascular Surgery. Lisbon, Portugal: 1993: 
106. 
118 DAVIES MG, KLYACHKIN ML, DALEN H, SVENDSEN E, HAGEN 
P-O. Regression of intimal hyperplasia with restoration of 
EDRF-mediated relaxation in experimental vein grafts. Surgery 
1993; 114: 258-271. 
119 FANN JL, SOKOLOFF MH, SARRIS GE, YUN KL, KOSEK JC, 
MILLAR DC. The reversibility of canine vein graft arterialization. 
Circulation 1990; 82 (Suppl IV): 9-18. 
120 DEAN RH, WILSON JP, BURKO H, FOSTER JH. Saphenous vein 
aortorenal bypass grafts: serial arteriographic study. Ann Surg 
1974; 180: 469-470. 
121 FOSTER JH, DEAN RH, PINKERTON JA, RHAMY RK. Ten years 
experience with the surgical management of renovascular 
hypertension. Ann Surg 1973; 177: 755. 
122 DAVIDSON ED, DEPALMA RG. Atherosclerotic aneurysm occur- 
ring in an autogenous vein graft. Am J Surg 1972; 124: 
112-114. 
123 DELARoCHA AG, PEIXOTO RS, BAIRD RJ. Atherosclerosis and 
aneurysm formation in a saphenous vein graft. Br J Surg 1973; 
60: 72-73. 
124 RIAHI M, VASU CM, TOMATIS LA, SCHLOSSER J, ZIMMERMAN 
E. Aneurysm of saphenous vein bypass graft to coronary artery. 
J Thorac Cardiovasc Surg 1975; 70: 358-359. 
125 STORM FK, GIERSON ED, SPARKS FC, BARKER WF. Autogenous 
vein bypass grafts: biological effects of mechanical dilatation and 
adventitial stripping in dogs. Surgery 1975; 77: 261-267. 
126 SZILAOYI DE, ELLIOTT JP, HAGEMAN JH, SMITH RF, SALLOLMO 
CA. Biologic fate of autogenous vein implants as arterial 
substitutes: clinical angiographic and histopathologic observa- 
tions in femoropopliteal operations for atherosclerosis. Ann Surg 
1973; 78: 232-246. 
127 NEITZEL GF, BARBORIAK JJ, PINTAR K, QUERSHI L. Athero- 
sclerosis in aortocoronary bypass grafts. Morphologic study and 
risk factor analysis 6 to 12 years after surgery. Arteriosclerosis 
1986; 6: 594-600. 
128 ATKINSON JB, FORMAN MB, VAUGHAN WK, et al. Morphologic 
changes in longterm saphenous vein bypass grafts. Chest 1985; 
88: 341-348. 
129 VIRAMI R, ATKINSON JB, FORMAN MB. Aortocoronary saphe- 
nous vein bypass grafts. Cardiovasc Clin 1988; 18: 41-59. 
130 O'DoNOHOE MK, RAD1C ZS, SCHWARTZ LB, MIKAT EM, 
McCANN RL, HAGEN P-O. Systemic hypertension alters vaso- 
motor function in experimental vein grafts. J Vasc Surg 1991; 14: 
30-39. 
131 LANDYMORE RW, KINLEY CE, CAMERON CA. Intimal hyper- 
plasia in autogenous vein grafts used for arterial bypass: a canine 
model. Cardiovasc Res 1985; 19: 589-592. 
132 KLYACHKIN ML, DAVIES MG, SVENDSEN E, et al. Hyper- 
cholesterolemia nd experimental vein grafts. Accelerated 
development of intimal hyperplasia nd abnormal vasomotor 
function. J Surg Res 1993; 54: 451-468. 
133 ROSENBLATT MS, QUIST WC, SIDAWY AN, PANISZYN CC, 
LoGERFO FW. Results of vein graft reconstruction f the lower 
extremity in diabetic and non-diabetic patients. Surg Gyneeol 
Obstet 1990; 171: 331-335. 
134 AMANO J, SUZUKI A, SUNAMORI M, TSUKADA T, NUMANO F. 
Cytokinetic study of aortocoronary bypass vein grafts in place 
for less than six months. Am J Cardiol 1991; 67: 1234-1236. 
135 SCOTT HWJ, MORGAN CV, BOLASNY BL, et al. Experimental 
atherosclerosis in autogenous venous grafts. Arch Surg 1970; 101: 
677. 
136 ZWOLAK RM, KIRKMAN TR, CLOWES AN. Atherosclerosis in
rabbit vein grafts. Arteriosclerosis 1989; 9: 374--379. 
137 LENZ M, HUGIqES H, RAYA J, TAYLOR A, GUYTON J. Vascular 
smooth muscle cell-mediated LDL oxidation; Loss of polyunsat- 
urated fatty acids and formation of specific lipid peroxidation 
products (abstract). FASEB J 1992; 6: A1323. 
138 TAPPEL A. Measurement of and protection from in vivo lipid 
peroxidation. In: PRYOR WA, ed. Free Radicals in Biology. San 
Diego: Academic Press, 1980; 1-47. 
139 PIOTROWSKI JJ, HUNTER GC, ESKELSON CD, et al. Lipid 
peroxidation: A possible factor in late graft failure of coronary 
artery bypass grafts. J Vasc Surg 1991; 13: 652-657. 
140 BECKMAN JS, BECKMAN TW, CHEN J, MARSHALL PA, FREEMAN 
BA. Apparent hydroxyl, radical production of peroxynitrite: 
implications for endothelial injury from nitric oxide and super- 
oxide. Proc Natl Acad Sci USA 1990; 87: 1620--1624. 
141 RUBANYI G. Vascular effects of oxygen derived free radicals. 
Free Radic Biol Med 1988; 4: 107-120. 
142 OALLE J, BASSANGE E, BUSSE R. Oxidized low density lipopro- 
teins potentiate vasoconstrictions to various agonists by direct 
interaction with vascular smooth muscle. Cir Res 1990; 66: 
1287-1293. 
143 SACHINIDOS A, MENGDEN T, LOCHER R, BRUNNER C, VETTER 
W. Novel cellular activities for low density lipoproteins in 
vascular smooth muscle cells. Hypertension 1990; 15: 704-711. 
144 FUSTER V. Progression-regression of atherosclerosis: molecular, 
cellular and clinical bases. Circulation 1992; 86 (Suppl III): 
1-123. 
145 MENCHACA HJ, MORRIS TJ, BOURDAGES H, NEFF T, MICHALEK 
VN, BUCHWALD H. Role of the mechanism of cholesterol 
reduction on vein graft atherosclerosis. Surgical Forum 1992; 
XLIII: 351-352. 
146 KLYACHKIN ML, DAVIES MG, KIM JH, et al. Post-operative 
reduction of high serum cholesterol concentrations and experi- 
mental vein bypass grafts: Effect on the development of intirnal 
hyperplasia and abnormal vasomotor function. J Thorac Cardio- 
vasc Surg 1994; 107: 556-566. 
147 BLANKENHORN DH, NESSIta SA, JOHNSON RL, SANMARCO ME, 
AZEN SP, CASHIN-HEMPHILL L. Beneficial effects of combined 
colestipol-niacin therapy on coronary atherosclerosis and coro- 
nary venous bypass grafts. JAMA 1987; 257: 3233-3240. 
148 SLADEN JG, GILMOUR JL. Vein graft stenosis: characteristics and 
effect of treatment. Am J Surg 1981; 141: 549-553. 
149 HOFF HF, BECK GJ, SKIBINSKI CJ, et al. Serum Lp(a) level as a 
predictor of vein graft stenosis after coronary artery bypass 
surgery in patients. Circulation 1988; 77: 1238-1244. 
150 CHESHIRE NJ, WOLFE JH, BARRADAS M, et al. Smoking and 
platelet activity predict infrainguinal graft stenosis. Br J Surg 
1993; 80: 520. 
151 BUCKLEY BH, HUTCmNS GM. Accelerated atherosclerosis: a 
morphological study of 97 saphenous vein coronary artery 
bypass grafts. Circulation 1977; 50: 163-169. 
152 LORENZ RL, WEBER M, KOTZUR J, et al. Improved aortocoro- 
nary bypass patency by low dose aspirin: effect on platelet 
aggregation and thromboxane formation. Lancet 1984; i: 
1261-1264. 
153 BOURASSA MG, CAMPEAU L, LESPERANCE J, GRONDIN CM. 
Changes in grafts and coronary arteries after saphenous vein 
aortocoronary bypass surgery: results at repeat angiography. 
Circulation 1982; 65 (Supple II): 90-97. 
154 CA/VIPEAU L, ENJALBERT M, LESPERANCE J, BAISLIC C, GRONDIN 
CM, BOURASSA MG. Atherosclerosis and late closure of 
aortocoronary saphenous vein grafts: sequential angiographic 
studies at 2 weeks, 1 year, 5 to 7 years and 10 to 12 years after 
surgery. Circulation 1983; 68 (Suppl I): 1-7. 
155 MANNICK JA. Improved limb salvage from modern infrainguinal 
artery bypass techniques. Surgery 1992; U l :  361-362. 
Eur J Vasc Endovasc Surg Vol 9, January 1995 
18 M.G. Davies and P.-O. Hagen 
156 FUSTER V, DYKEN ML, VOKONAS PS, et al. AHA Medical/ 
scientific statement: aspirin as a therapeutic agent in cardiovas- 
cular disease. Circulation 1993; 87: 659-675. 
157 MCCANN RL, HAGEN P-O, FUCHS JCA. Aspirin and dipyr- 
idamole decrease intimal hyperplasia nexperimental vein grafts. 
Ann Surg 1980; 191: 238-243. 
158 HIRKO MK, McSHANNIC JR, SCHMIDT SP, et al. Pharmacologic 
modulation of intimal hyperplasia in canine vein grafts. J Vasc 
Surg 1993; 17: 877-887. 
159 BOERBOOM LE, OLINGER GN, LIU TZ, RODRIGUEZ ER, 
FERRANS VJ, KlSSELBAH AH. Histologic, morphometric and 
biochemical evaluation of vein grafts in a nonhuman primate 
model. II modification of early changes by platelet inhibition 
with aspirin and dipyridamole. J Thorac Cardiovasc Surg 1990; 
99: 10%112. 
160 HAGEN P-O, DAVIES MG, SCHUMAN RW, MURRAY JJ. Reduc- 
tion of vein graft intimal area by ex-vivo treatment with 
desferroxamine manganese. J Vasc Res 1992; 29: 405-409. 
• 161 DAVIES MG, BARBER L, DALEN H, SV'ENDSEN E, HAGEN P-O. 
Pharmacologic control of the structural and functional conse- 
quences of vein graft intimal hyperplasia by a 21-aminoste~oid 
(U74389G). Eur J Vasc Surg 1994; 8: 448-456. 
162 ELSANADIKI MN, CROSS KS, MURRAY JJ, et al. Reduction of 
intimal hyperplasia and enhanced reactivity of experimental vein 
bypass grafts with verapamil treatment. Ann Surg 1990; 212: 
87-96. 
163 PEARCE JE, DUJOVNY M, Ho KL, et al. Acute inflammation and 
endothelial injury in vein grafts. Neurosurgery 1985; 17: 
626-634. 
164 BROI~y WR, BROWN JW, REITZ BA, FRY DL, MICHAEl;IS DL. 
Effects of dipyridamole and methylprednisolone on intimal 
thickening in vein grafts. J Thorac Cardiovasc Surg 1977; 73: 
602-604. 
165 O'DoNOHOE MK, SCHWARTZ LB, RADIC ZS, MIKAT EM, 
MCCANN RL, HAGEN P-O. Chronic ACE inhibition reduces 
intimal hyperplasia in experimental vein grafts. Ann Surg 1991; 
214: 727-732. 
166 MASSEY MF, DAVIES MG, SVENDSEN E, KLYACHKIN ML, 
BARBER L, HAGEN P-O. Ketansefin inhibits experimental vein 
graft intimal hyperplasia. Y Surg Res 1993; 54: 530-538. 
167 NOP, MAN PE, HOUSE AK. Influence of prazosin on experimental 
vein graft intimal thickening. Br J Surg 1992; 79: 276-279, 
168 MAKHOUL RG, DAVIS WS, McCANN RL, HAGEN P-O. Heparin 
decreases intimal hyperplasia in experimental vein bypass grafts 
(abstract). Circulation 1986; 74 (Supple II): II-26. 
169 KOHLER TR, KIRKMAN T, CLOWES AW. Effect of heparin on 
adaptation of vein grafts to arterial circulation. Arteriosclerosis 
1989; 9: 523-528. 
170 CAMBRIA RP, IVARSSON BL, FALLON JT, ABBOTT WM. Heparin 
fails to suppress intimal proliferation i experimental vein grafts. 
Surgery 1992; 111: 424-429. 
171 WILSON NV, SALISBURY JR, KAKKAR VV. The effect of low 
molecular weight heparin on intimal hyperplasia in vein grafts. 
Eur J Vasc Surg 1994; 8: 60-64. 
172 CALCAGNO D, CONTE JV, HOWELL MH, FOEGH ML. Peptide 
inhibition of neointimal hyperplasia in vein grafts. J Vasc Surg 
1991; 13: 475-479. 
173 DAVIES MG, KIM JH, MAKHOUI- RG, DALEN H, SVZNDSEN E, 
HAGEN P-O. Reduction of intimal hyperplasia nd preservation 
of Nitric Oxide (NO)-mediated relaxation by the NO precursor: 
L-arginine. Surgery 1994; 116: 557-568. 
174 CAHILL PD, SARRIS GE, COOPER AD, et al. Inhibition of vein 
graft intimal thickening by eicosapentaenoic a id: Reduced 
thromboxane production without changes in lipoprotein levels 
or low density lipoprotein receptors density. J Vasc Surg 1988; 7: 
108-117. 
175 LANDYMORE RW, MANKU MS, TAN M, MACAULAY MA, 
SHERMAN B. Effects of low dose marine oils on intimal 
hyperplasia in autologous vein grafts. Y Thorac Cardiovasc Surg 
1989; 98: 788-791. 
Eur J Vasc Endovasc Surg Vol 9, January 1995 
